Skip to main content
OpenTrials
Completed

NCT Number: NCT03365934

Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds

This single center, randomized, 15-day clinical trial is being conducted to assess the changes to the skin microbiome of induced wounds on the back in approximately 35 healthy adult subjects aged 18-55 years, with Fitzpatrick Skin Types I - III. Microbiome and skin physiology assessments will be completed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

TKL Research Inc.

Fair Lawn, New Jersey, 07410, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 to 55 years of age.
  • Fitzpatrick skin types I to III.
  • Must be able to comprehend and follow the requirements of the study
  • Avoid excessive sun exposure
  • Willing to refrain from topical product use on the back for the duration of the study.
  • Subjects must agree not to immerse their bandages in water for the duration of the study.
  • Male and female subjects with reproductive potential who agree to practice a medically acceptable form of birth control

Exclusion criteria

  • Excessively hairy back, acne, scars and pigmentation or nevi t
  • . Pregnant or Lactating, or planning on becoming pregnant;
  • . Known allergies or sensitivities to anesthetics, adhesive bandages, wound treatment products or tapes;
  • . Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results
  • Participation in any other clinical study within 30 days of Visit 1;
  • . Subjects who have a health condition and/or pre-existing or dormant dermatologic conditions or who have clinically active bacterial, fungal, or viral skin infections or those who are susceptible to cutaneous infections
  • Subjects who report using prescription or OTC medication (oral or topical) that can make skin more sensitive or influence the skin (i.e. antibiotics, hormones, insulin, etc.)
  • Subjects receiving topical and/or inhaled medications that may alter or compromise the bleeding/healing process
  • Individuals with a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications and/or radiation
  • . Subjects with a known history of keloid or hypertrophic scar formation;
  • Subjects diagnosed with any blood clotting disorder;
  • Hyperthyroidism or hypothyroidism or with active or recently treated (within 1 year) skin cancer, or those in poor nutritional status; 13 Subjects taking oral Vitamin A derivatives such as Accutane, isotretinon, or using retinoic acid in the past 1 year or using topical Vitamin A derivatives in the 3 weeks prior to study start;
  • Subjects with clinically infected skin lesions; 15. Subjects with cracked or excoriated skin, or other skin problems. 16. Diabetes mellitus that cannot be controlled by diet alone (i.e. requires systemic medications for control); 17. Subjects with friable skin, at the discretion of the Investigator;

Treatment and study plan

ADHESIVE BANDAGE #1

Device

Bandage applied daily to wounded site for 14 days

ADHESIVE BANDAGE #2

Device

Bandage applied daily to wounded site for 14 days

ADHESIVE BANDAGE #3

Device

Bandage applied daily to wounded site for 14 days

Antibacterial Bandage with 0.8% BZK

Device

bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days

Intact and No Bandage

Other

This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.

Wounded and No Bandage

Other

This test site will be wounded but will not be treated with a bandage, serving as the positive control site.

Primary outcomes

  1. Microbial Community Richness - Baseline (Day 0)

    Time frame: Baseline (Day 0)

    Swabs will be collected on the back at Baseline (Day 0) and analyzed to determine the total number of different bacterial taxa (microorganisms) detected in the sample. There was no prespecified primary endpoint in the protocol.

  2. Microbial Community Richness - (Day 1)

    Time frame: Day 1

    Swabs will be collected on the back at Day 1 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.

  3. Microbial Community Richness - (Day 2)

    Time frame: Day 2

    Swabs will be collected on the back at Day 2 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.

  4. Microbial Community Richness - (Day 3)

    Time frame: Day 3

    Swabs will be collected on the back at Day 3 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.

  5. Microbial Community Richness - (Day 4)

    Time frame: Day 4

    Swabs will be collected on the back at Day 4 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.

  6. Microbial Community Richness - (Day 5)

    Time frame: Day 5

    Swabs will be collected on the back at Day 5 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.

  7. Microbial Community Richness - (Day 6)

    Time frame: Day 6

    Swabs will be collected on the back at Day 6 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.

  8. Microbial Community Richness - (Day 7)

    Time frame: Day 7

    Swabs will be collected on the back at Day 7 and analyzed to determine the total number of different bacteria Taxa (microorganismss) detected in the sample.

  9. Microbial Community Richness - (Day 14)

    Time frame: Day 14

    Swabs will be collected on the back at Day 14 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.

  10. Microbial Community Diversity - Baseline (Day 0)

    Time frame: Baseline (Day 0)

    Swabs will be collected on the back at Baseline (Day 0) for analysis based on the Shannon Index.

  11. Microbial Community Diversity - Day 1

    Time frame: Day 1

    Swabs will be collected on the back at Day 1 for analysis based on the Shannon Index.

  12. Microbial Community Diversity - Day 2

    Time frame: Day 2

    Swabs will be collected on the back at Day 2 for analysis based on the Shannon Index.

  13. Microbial Community Diversity - Day 3

    Time frame: Day 3

    Swabs will be collected on the back at Day 3 for analysis based on the Shannon Index.

  14. Microbial Community Diversity - Day 4

    Time frame: Day 4

    Swabs will be collected on the back at Day 4 for analysis based on the Shannon Index.

  15. Microbial Community Diversity - Day 5

    Time frame: Day 5

    Swabs will be collected on the back at Day 5 for analysis based on the Shannon Index.

  16. Microbial Community Diversity - Day 6

    Time frame: Day 6

    Swabs will be collected on the back at Day 6 for analysis based on the Shannon Index.

  17. Microbial Community Diversity - Day 7

    Time frame: Day 7

    Swabs will be collected on the back at Day 7 for analysis based on the Shannon Index.

  18. Microbial Community Diversity - Day 14

    Time frame: Day 14

    Swabs will be collected on the back at Day 14 for analysis based on the Shannon Index.

  19. Microbial Community Evenness - Baseline (Day 0)

    Time frame: Day 0

    Swabs will be collected on the back at Baseline (Day 0) for analysis based on the Pielou's Evenness Index.

  20. Microbial Community Evenness - Day 1

    Time frame: Day 1

    Swabs will be collected on the back at Day 1 for analysis based on the Pielou's Evenness Index.

  21. Microbial Community Evenness - Day 2

    Time frame: Day 2

    Swabs will be collected on the back at Day 2 for analysis based on the Pielou's Evenness Index.

  22. Microbial Community Evenness - Day 3

    Time frame: Day 3

    Swabs will be collected on the back at Day 3 for analysis based on the Pielou's Evenness Index.

  23. Microbial Community Evenness - Day 4

    Time frame: Day 4

    Swabs will be collected on the back at Day 4 for analysis based on the Pielou's Evenness Index.

  24. Microbial Community Evenness - Day 5

    Time frame: Day 5

    Swabs will be collected on the back at Day 5 for analysis based on the Pielou's Evenness Index.

  25. Microbial Community Evenness - Day 6

    Time frame: Day 6

    Swabs will be collected on the back at Day 6 for analysis based on the Pielou's Evenness Index.

  26. Microbial Community Evenness - Day 7

    Time frame: Day 7

    Swabs will be collected on the back at Day 7 for analysis based on the Pielou's Evenness Index.

  27. Microbial Community Evenness - Day 14

    Time frame: Day 14

    Swabs will be collected on the back at Day 14 for analysis based on the Pielou's Evenness Index.

Secondary outcomes

  1. Skin Barrier Function -Baseline (Day 0)

    Time frame: Day 0

    The skin barrier function of the test sites will be evaluated at Baseline (Day 0) by Trans Epidermal Water Loss (TEWL).

  2. Skin Barrier Function - Day 1

    Time frame: Day 1

    The skin barrier function of the test sites will be evaluated at Day 1 by Trans Epidermal Water Loss (TEWL).

  3. Skin Barrier Function - Day 2

    Time frame: Day 2

    The skin barrier function of the test sites will be evaluated at Day 2 by Trans Epidermal Water Loss (TEWL).

  4. Skin Barrier Function - Day 3

    Time frame: Day 3

    The skin barrier function of the test sites will be evaluated at Day 3 by Trans Epidermal Water Loss (TEWL).

  5. Skin Barrier Function - Day 4

    Time frame: Day 4

    The skin barrier function of the test sites will be evaluated at Day 4 by Trans Epidermal Water Loss (TEWL).

  6. Skin Barrier Function - Day 5

    Time frame: Day 5

    The skin barrier function of the test sites will be evaluated at Day 5 by Trans Epidermal Water Loss (TEWL).

  7. Skin Barrier Function - Day 6

    Time frame: Day 6

    The skin barrier function of the test sites will be evaluated at Day 6 by Trans Epidermal Water Loss (TEWL).

  8. Skin Barrier Function - Day 7

    Time frame: Day 7

    The skin barrier function of the test sites will be evaluated at Day 7 by Trans Epidermal Water Loss (TEWL).

  9. Skin Barrier Function - Day 14

    Time frame: Day 14

    The skin barrier function of the test sites will be evaluated at Day 14 by Trans Epidermal Water Loss (TEWL).

  10. Redness: Wound Area Oxyhemoglobin Level- Baseline (Day 0)

    Time frame: Day 0

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

  11. Redness: Wound Area Oxyhemoglobin Level - Day 1

    Time frame: Day 1

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

  12. Redness: Wound Area Oxyhemoglobin Level - Day 2

    Time frame: Day 2

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

  13. Redness: Wound Area Oxyhemoglobin Level - Day 3

    Time frame: Day 3

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

  14. Redness: Wound Area Oxyhemoglobin Level - Day 4

    Time frame: Day 4

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

  15. Redness: Wound Area Oxyhemoglobin Level - Day 5

    Time frame: Day 5

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

  16. Redness: Wound Area Oxyhemoglobin Level - Day 6

    Time frame: Day 6

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

  17. Redness: Wound Area Oxyhemoglobin Level - Day 7

    Time frame: Day 7

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

  18. Redness: Wound Area Oxyhemoglobin Level - Day 14

    Time frame: Day 14

    Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Consumer Inc. (J&JCI)

Industry

Registry information

Official study title

Randomized, Exploratory Study to Evaluate Changes to Skin Microbiome With Tape-stripped Wounds

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Dec 8, 2017
Registry last updated
Jun 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.